Vaccination of Women against Human Papillomaviruses in the Czech Republic (Enrolment Data)

Česká verzia

Authors: Eva Hamšíková ¹; Jana Šmahelová ¹; Viera Ludvíková ¹; Martina Saláková ¹; Jana Rychlá ¹; Jana Skřenková ²; Lukáš Rob ³; Ruth Tachezy ¹
Authors place of work: Oddělení experimentální virologie, NRL pro papilomaviry, Ústav hematologie a krevní transfuze, Praha ¹; Gynekologicko-porodnická klinika, 1. LF UK a VFN, Praha ²; Gynekologicko-porodnická klinika, 2. LF UK a FN Motol, Praha ³
Published in the journal: Prakt Gyn 2014; 18(4): 230-235
Category: Gynecology and Obstetrics

Summary

High-risk human papillomaviruses (HR HPV) are causally linked to cervical cancer (CC) and some other malignancies. The currently available HPV vaccines contain antigens of two HR HPV types, HPV16 and HPV18 that account for more than 70% of CC in the Czech Republic. The study objective was to monitor the prevalence of HPV infection markers in the vaccinated population, to detect past, present, and persistent HPV infection, and to assess the effect of vaccination on subsequent HPV infection and development of atypical cervical lesions. Here we present the baseline prevalence data on the of HPV infection markers at enrolment. Overall, 37.4% of the study cohort were HPV DNA positive, half of the females were seropositive to at least one of the antigens tested, and nearly one quarter had antibodies against HPV16/18 types. Present/persistent/past infection with HPV16/18 types was detected in 4.7%/6.7%/15.4% of the females, respectively. Altogether 11.4% of the study cohort are at risk for reduced vaccine efficacy against HPV16/18, with the risk being highest in the age group 24–26 years (22.6%).

Key words:
antibodies – HPV – HPV DNA – infection – vaccination

Zdroje

1. Boshart M, Gissmann L, Ikenberg H et al. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 1984; 3(5): 1151–1157.

2. Dürst M, Gissmann L, Ikenberg H et al. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983; 80(12): 3812–3815.

3. De Martel C, Ferlay J, Franceschi S et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13(6): 607–615.

4. Guan P, Howell-Jones R, Li N et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131(10): 2349–2359.

5. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30(Suppl 5): F123-F138.

6. Schmitt M, Dondog B, Waterboer T et al. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol 2008; 46(3): 1050–1059.

7. van den Brule AJC, Pol R, Fransen-Daalmeijer N et al. GP5+/6+PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002; 40(3): 779–787.

8. Tachezy R, Smahelova J, Kaspirkova J et al. Human papillomavirus type-specific prevalence in the cervical cancer screening population of Czech women. PLoS One 2013; 8(11): e79156. Dostupné z DOI: <http://doi: 10.1371/journal.pone.0079156>.

9. Tachezy R, Mikyskova I, Ludvikova V et al. Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies. Eur J Clin Microbiol Infect Dis. 2006; 25(8): 492–500.

10. Smith EM, Ritchie JM, Pawlita M et al. Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer 2007; 120(4): 825–832.

11. Hrbacek J, Urban M, Hamsikova E et al. Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study. BMC Cancer 2011; 11: 53. Dostupné z DOI: <http://doi: 10.1186/1471–2407–11–53>.

12. Bernard HU, Burk RD, Chen Z et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401(1): 70–79.

13. Nasman A, Attner P, Hammarstedt L et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009; 125(2): 362–366.

14. Brewster DH, Bhatti LA. Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975–2002. Br J Cancer 2006; 95(1):87–90.

15. de Sanjose S, Cortes X, Mendez C et al. Age at sexual initiation and number of sexual partners in the female Spanish population Results from the AFRODITA survey. Eur J Obstet Gynecol Reprod Biol 2008; 140(2): 234–240.

16. Crow JM. HPV: The global burden. Nature 2012; 488(7413): S2-S3.

17. Tachezy R, Smahelova J, Salakova M, et al. Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPV. PLoS One 2011; 6(7): e21913. Dostupné z DOI: <http://doi: 10.1371/journal.pone.0021913>.

18. Rotnaglova E, Tachezy R, Salakova M et al. HPV involvement in tonsillar cancer: Prognostic significance and clinically relevant markers. Int J Cancer 2011; 129(1): 101–110.

19. Hamsikova E, Ludvikova V, Stasikova J et al. Cross-sectional study on the prevalence of HPV antibodies in the general population of the Czech Republic. Sex Transm Infect 2013; 89(2): 133–137.